Panelists discuss an alternative dosing schedule for sunitinib and the CARMENA, SURTIME, and RECORD-3 trials, which focus on the frontline treatment of patients with metastatic renal cell carcinoma.

To view more from this discussion, visit [ Ссылка ]

свернуть